Introduction:
As the landscape that surrounds Covid changes with each day, one thing has remained constant, the mention of Pfizer’s “noble” efforts to combat the everlasting “pandemic” we all have become so accustomed to. In March of 2021, Pfizer announced a new oral antiviral therapeutic to aid in the effort against Covid, had begun phase 1 clinical trials. The composition and function of the new oral antiviral sounds eerily similar to that of Ivermectin. In this article, I plan to highlight the striking similarities between Pfizer’s oral antiviral drug and the drug Ivermectin, as well as compare the function and mechanism of action between the two drugs. According to studies and available data, it appears Pfizer is rebranding Ivermectin with the intention of inflating the price and selling it as their own. Pfizer has been exposed for the perpetration of a “bait and switch” on the general public with regard to the “FDA approval” of their vaccine, could Pfizer be attempting the same level of deception with this new oral antiviral treatment? Since the vaccine has been proven to be ineffective and vaccination rates have plateaued, could this be a deranged effort to force every individual into compliance?
In order to understand the “bait and switch” reference, I suggest reading part 5 of my Truth About Covid series. I go into great detail about the stunt that the FDA and Pfizer perpetrated onto the general public with the alleged “FDA approval” of Pfizer’s vaccine. Hint: Pfizer’s vaccine available in the United States is NOT FDA approved, they are intentionally LYING to you. Feel free to fact check that claim, Pfizer’s own documents explicitly state this.
He who permits himself to tell a lie once, finds it much easier to do it a second and third time, till at length it becomes habitual; he tells lies without attending to it, and truths without the world’s believing him. This falsehood of the tongue leads to that of the heart, and in time depraves all its good dispositions. - Thomas Jefferson
Pfizer’s Oral Antiviral Treatment For Covid:
The pharmaceutical giant Pfizer, made the announcement of an oral antiviral treatment for Covid currently undergoing clinical trials. This new drug to help combat Covid is a protease inhibitor, named PF-07321332. For an individual to become infected, the virus penetrates the body’s cells and multiplies to create more virus. Proteases are enzymes that enable the multiplication of the virus, the virus’s protease enzyme splits proteins in the body, which allows the viral replication of the virus. When proteases are met with an inhibitor, it stops the enzyme’s ability to split these proteins and ultimately inhibits the virus’s ability to replicate. The main protease in Covid responsible for splitting the body’s proteins is called 3CL and the oral antiviral would primarily target this protease and inhibit the enzyme’s ability to replicate.
Pfizer’s Covid vaccine was designed to provoke an immune response (immunogenicity), to teach the body how to combat the virus. Pfizer’s oral antiviral treatment is designed to inhibit viral replication of the virus, when an individual is first exposed to the virus. The vaccines have been proven to be ineffective at stopping the transmission and infection of the virus and the desired immune response has not materialized as initially suggested. Now, Pfizer is taking another approach at combatting the virus through the inhibition of the virus’s ability to replicate after exposure to the virus. The oral antiviral is a form of early treatment, which has been scientifically proven to be the most effective way to fight Covid.
The main points to take from this section:
Pfizer’s oral antiviral drug is a protease inhibitor designed to eliminate viral replication of the virus, through the inhibition of the protease enzyme 3CL. This oral antiviral is designed to be used as a form of early treatment against Covid.
Ivermectin Protease Inhibitor:
Ivermectin is a multi-faceted drug that is on the WHO’s list of essential medicines and the founders of the medication were awarded a Nobel Prize in 2015, for their discovery. The use of Ivermectin as a treatment for Covid has been extremely polarized, public officials and the media have dubbed the drug as solely a “horse dewormer,” which is inherently false. There is sufficient data proving that Ivermectin is safe and effective when used as an early treatment for Covid. I’m not going to go into great detail about Ivermectin and Covid, part 3 of my Truth About Covid series provides a great deal of information that pertains to this subject. In this section, I will highlight the medical profile of Ivermectin and how the drug works to combat Covid.
Exploring the Binding Efficacy of Ivermectin Against the Key Proteins of SARS-CoV-2 pathogenesis:
To understand the similarities between Pfizer’s antiviral treatment and Ivermectin as treatments for Covid, one must understand the role Ivermectin plays when used as a treatment for Covid. A research article from Future Virology, focused on Ivermectin’s ability to bind with key proteins in SARS-CoV-2 pathogenesis. The interaction of Ivermectin against these key proteins, was investigated through molecular docking and molecular dynamic simulation. The study concluded that Ivermectin blocked Covid’s viral replicase, main protease and human TMPRSS2, which in turn, could be the biophysical basis behind its antiviral efficiency. This study proves Ivermectin is efficient at binding and disrupting SARS-CoV-2 key proteins, thus inhibiting viral replication of the virus. Sound familiar?
Ivermectin was found as a blocker of viral replicase, protease and human TMPRSS2, which could be the biophysical basis behind its antiviral efficiency. The antiviral action and ADMET profile of ivermectin was on par with the currently used anticorona drugs such as hydroxychloroquine and remdesivir.
SARS-CoV-2 uses a protease enzyme, namely chymotrypsin-like protease (3CLpro) or main protease (Mpro), which perform an important function to prime spike protein-mediated binding to human ACE2 and entry of the virus [3]. Herein, we checked the interaction between ivermectin and the viral protease and found a strong hydrophobic interaction between these two (Figure 1B & Table 1). Interestingly, the binding efficacy of ivermectin to SARS-CoV-2 replicase/RDRP was to found to be relatively high (Figure 2A–B & Table 1). In fact, ivermectin was found to be the best out of the three drugs in binding with viral replicase.
The present study depicts comparative binding efficacy of a promising FDA-approved drug, ivermectin, against major pathogenic proteins of SARS-CoV-2 and their human counterparts involved in host–pathogen interaction. Herein, our in silico data have indicated that ivermectin efficiently utilizes viral spike protein, main protease, replicase and human TMPRSS2 receptors as the most possible targets for executing its antiviral efficiency. Therefore, ivermectin exploits protein targets from both virus and human, which could be the reason behind its excellent in vitro efficacy against SARS-CoV-2 as reported by Caly et al.
This research article concludes Ivermectin’s efficiency to bind to the key proteins involved in SARS-CoV-2 pathogenesis and highlights the drug’s ability to bind with Covid’s main protease (3CL), the main protease enzyme needed for viral replication. The ability to bind with these proteins, further proves Ivermectin’s antiviral efficiency. Similarly, a protease inhibitor must possess the ability to bind with these key proteins, in order to inhibit viral replication of a virus.
The Mechanisms of Action of Ivermectin Against SARS-CoV-2:
The majority of studies that surround Ivermectin being an effective treatment for Covid, have focused on the drug being used as an early prophylactic treatment. An evidence based clinical review from the Journal of Antibiotics, focused on the mechanisms of action of Ivermectin against Covid-19 and reviewed 55 studies that evaluated its efficiency as an early treatment and prophylactic. The review illustrated Ivermectin’s interaction with the key proteins in SARS-CoV-2 pathogenesis and proved its ability to bind and disrupt Covid’s main protease needed for viral replication (3CL). This review concluded that Ivermectin has antiviral properties and shows significant promise when used as an early treatment due to its ability to inhibit viral replication of the virus.
An In-silico data analysis conducted by Choudhury et al. demonstrated that Ivermectin efficiently utilizes viral spike protein, main protease, replicase, and human TMPRSS2 receptors as the most possible targets for executing its “antiviral efficiency” by disrupting binding. Since Ivermectin exploits protein targets from both, the virus and human, this could be the behind its excellent in vitro efficacy against SARS-CoV-2.
Once gaining entry into the host cell, the viral RNA is translated by the host ribosome into a large “polyprotein”. Some enzymes break away through autoproteolysis from this polyprotein and further help other proteins to break off and carry out their function for replication. One such enzyme, 3 chymotrypsin-like proteases (3’cl pro/ Mpro) is responsible for working on this polyprotein causing other proteins to “librate” and carry out viral replication. Ivermectin binds to this enzyme and disrupts it. It also efficiently binds to both proteins, Mpro, and to a lesser extent to PLpro of SARS-CoV-2; therefore, it has a role in preventing the post-translational processing of viral polyproteins.
This evidence based clinical review concluded that Ivermectin has proven to be effective when used as an early treatment and in prophylaxis. They also concluded Ivermectin has antiviral properties and exploits protein targets from both the human and the virus. The review also showed Ivermectin disrupts and binds to Covid’s main protease responsible for viral replication (3CL), which in turn prevents further replication through the disruption of the protease.
The information provided proves Ivermectin possesses the ability to bind with the key proteins in SARS-CoV-2 pathogenesis and ability to disrupt key proteins which inhibits viral replication. The studies show that Ivermectin is efficient when used as an early treatment and in prophylaxis. Both studies highlighted its antiviral efficiency when used as a treatment for Covid. Information from these studies suggests that Ivermectin can serve as a protease inhibitor, due to its antiviral efficiency and inhibition of viral replication. Interestingly enough, Pfizer’s new oral protease inhibitor aims to inhibit the binding ability of Covid’s main protease (3CL), which disrupts viral replication of the virus. In other words, Pfizer is creating a new oral antiviral treatment that does the exact same thing Ivermectin has been proven to do.
Pfizermectin:
Pfizer has an oral antiviral treatment undergoing clinical trials, which is designed to serve as a protease inhibitor. Protease inhibitors bind to key proteins and inhibit viral replication through the disruption of viral pathogenesis. Pfizer’s protease inhibitor primarily targets SARS-CoV-2 main protease 3CL and seeks to inhibit viral replication through disruption of the enzymes binding ability. Pfizer’s oral antiviral treatment is designed to be used as an early treatment to combat Covid.
The function of Pfizer’s oral antiviral is to bind to Covid’s key proteins, including the main protease (3CL) responsible for viral replication. The mechanism of action of this antiviral is to inhibit the binding ability of the protease 3CL and which disrupts viral replication. Keep in mind, this drug is still undergoing clinical trials, meaning the function and mechanism of action are speculative.
Ivermectin is a multi-faceted drug and on the WHO’s list of essential medicines, that has been studied as a possible alternative treatment for Covid. Available data from other countries and numerous studies suggest that Ivermectin is an effective early treatment and prophylactic against Covid. The drug has been proven to possess antiviral properties and recent studies show its ability to bind with key proteins, which includes SARS-CoV-2 main protease 3CL, responsible for viral replication. Additional studies show Ivermectin has the ability to inhibit the virus’s key proteins, as well as the inhibition of the main protease (3CL). When used as an early treatment and prophylactic, Ivermectin has shown significant effectiveness against Covid.
Due to the antiviral properties of Ivermectin, the function of the drug is the ability to bind to the virus’s key proteins, including Covid’s the main protease (3CL). Ivermectin’s mechanism of action is the inhibition of key proteins, including the inhibition of the main protease 3CL which disrupts viral replication of the virus. Keep in mind, studies and available data have proven the effectiveness of its function and mechanism of action against SARS-CoV-2.
Final Points:
As one can see, Pfizer is developing an oral antiviral treatment that possesses the same function and mechanism of action as Ivermectin. The difference between the two, is that Pfizer’s protease inhibitor is still undergoing clinical trials and completed studies prove Ivermectin possesses the ability to serve as a protease inhibitor. It doesn’t take a rocket scientist to realize the striking similarities between the two drugs. The issue is that Pfizer will inflate prices for their oral antiviral in order to increase profits under the guise of a “medical breakthrough.” Meanwhile, Ivermectin is extremely cost effective and has been used for medical purposes in humans for almost 40 years.
This article was written based on available data that surround both drugs and ability to make connections from said data. The only way to confirm this hypothesis is by testing the composition of both drugs and compare the findings. In order to further understand the concepts that surround Covid, I highly suggest reading all five parts of my Truth About Covid series. Pfizer is notorious for deceiving and misleading the public about their products (google: largest criminal fine in history), the company’s lawsuit and recall history, sufficiently proves this. Pfizer lied to the public about their vaccine receiving “FDA approval,” the safety and efficacy of the vaccine and about aborted fetal tissue in the vaccines. Project Veritas released a Pfizer employee whistleblower video on October 6th and everyone needs to see what the employee provided. The latest story from Project Veritas further solidifies these claims against Pfizer. I hope this article helps provoke thought and prompts individuals to conduct their own research about these topics.